Most Read Articles
Roshini Claire Anthony, 10 Jul 2019

Women who receive a single dose of amoxicillin and clavulanic acid within 6 hours of operative vaginal delivery could significantly reduce their postpartum infection risk, according to the UK-based ANODE* trial.

17 Jun 2019
Podcast: Dr Sara Hurvitz highlights that the addition of ribociclib to endocrine therapy improved overall survival in premenopausal women with HR+, HER2- advanced breast cancer, according to the MONALEESA-7 trial.
Audrey Abella, 05 Jul 2018
The addition of the sodium-glucose cotransporter-2 inhibitor ertugliflozin to metformin improved glycaemic control, body weight, and blood pressure (BP) in patients with inadequately controlled type 2 diabetes (T2D), according to the results of the VERTIS MET* trial presented at ADA 2018.
17 Feb 2019
In patients with type 2 diabetes (T2D), sodium-glucose cotransporter 2 (SGLT2) inhibitor monotherapy, particularly canagliflozin, exerts greater effects on weight compared with metformin and dipeptidyl peptidase 4 (DPP-4) inhibitors or gliptins, according to the results of a meta-analysis.

Statin use may lower risks of osteoporosis, fracture in stroke patients

11 Oct 2018

Use of statin appears to reduce the risks of osteoporosis, hip fractures and vertebral fracture in patients newly diagnosed with a stroke, suggests a recent study.

Poststroke statin use correlated with a decreased overall risk of the primary outcome of osteoporosis, hip fractures and vertebral fracture (adjusted hazard ratio [aHR], 0.66; p<0.001). Subanalyses revealed a correlation between statin use and a lower risk of all individual outcomes, including osteoporosis (aHR, 0.68; p<0.001), hip fracture (aHR, 0.59; p<0.001) and vertebral fracture (aHR, 0.73; p=0.003).

There was a dose-effect relationship between the outcomes and statin use. The aHRs for developing the primary outcome were 0.96 for patients who used 1–90 cumulative defined daily doses of statins, 0.86 for 91–365 and 0.34 for >365. These dose-effect relationships persisted in subgroup analyses stratified by age, sex and stroke type and sensitivity analyses conducted without propensity score matching.

This population-based propensity score-matched cohort study examined the association between statin use and risks of osteoporosis and fracture in stroke patients using Taiwan’s National Health Insurance Research Database.

The authors identified patients newly diagnosed with a stroke between 2000 and 2012. A total of 5,254 patients were included after propensity-score matching. Cox proportional hazards regression models according to statin use status were generated to calculate HRs for poststroke osteoporosis, hip fracture and vertebral fracture.

“Poststroke osteoporosis and consequent fractures increase the risk of morbidity and mortality and cause considerable socioeconomic burden,” the authors noted.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 10 Jul 2019

Women who receive a single dose of amoxicillin and clavulanic acid within 6 hours of operative vaginal delivery could significantly reduce their postpartum infection risk, according to the UK-based ANODE* trial.

17 Jun 2019
Podcast: Dr Sara Hurvitz highlights that the addition of ribociclib to endocrine therapy improved overall survival in premenopausal women with HR+, HER2- advanced breast cancer, according to the MONALEESA-7 trial.
Audrey Abella, 05 Jul 2018
The addition of the sodium-glucose cotransporter-2 inhibitor ertugliflozin to metformin improved glycaemic control, body weight, and blood pressure (BP) in patients with inadequately controlled type 2 diabetes (T2D), according to the results of the VERTIS MET* trial presented at ADA 2018.
17 Feb 2019
In patients with type 2 diabetes (T2D), sodium-glucose cotransporter 2 (SGLT2) inhibitor monotherapy, particularly canagliflozin, exerts greater effects on weight compared with metformin and dipeptidyl peptidase 4 (DPP-4) inhibitors or gliptins, according to the results of a meta-analysis.